RANDOMIZED STUDY OF VAC VS VAC ALTERNATING WITH VTC IN INTERMEDIATE RISK RMS

中等风险 RMS 中 VAC 与 VAC 与 VTC 交替的随机研究

• 批准号: 7375483
• 负责人: YOUSIF H MATLOUB
• 金额: $ 5.05万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7375483
• 关键词: RANDOMIZED; STUDY; VAC; VS; ALTERNATING

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is closed to further accrual. (Clinical trial summary from the National Cancer Institute's PDQ database) Drugs used in chemotherapy, such as dactinomycin, cyclophosphamide, vincristine, and topotecan, use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective in treating rhabdomyosarcoma. This randomized phase III trial is comparing two different combination chemotherapy regimens to see how well each works in treating patients with previously untreated rhabdomyosarcoma or sarcoma.

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。这项研究已经结束，不会有进一步的收益。(来自国家癌症研究所PDQ数据库的临床试验摘要)化疗中使用的药物，如放线菌素、环磷酰胺、长春新碱和拓扑替康，使用不同的方法阻止肿瘤细胞分裂，从而停止生长或死亡。目前尚不清楚哪种联合化疗方案治疗横纹肌肉瘤更有效。这项随机的III期试验正在比较两种不同的联合化疗方案，看看每种方案在治疗以前没有治疗过的横纹肌肉瘤或肉瘤患者中的效果如何。